OncoGenex Pharmaceuticals Company Profile (NASDAQ:OGXI)

About OncoGenex Pharmaceuticals (OGXI)

OncoGenex Pharmaceuticals logoOncoGenex Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in the development and commercialization of therapies that address treatment resistance in cancer patients. The Company's segment is dedicated to the development and commercialization of cancer therapies, with operations located in Canada and the United States. The Company's product candidates include Custirsen, Apatorsen and OGX-225. The Company is focused on targeting these particular proteins to disable the tumor cell's adaptive defenses, thereby rendering the tumor cells susceptible to attack with a range of cancer therapies. Of these product candidates, Custirsen and Apatorsen are clinical-stage assets. Custirsen is being evaluated in two Phase III trials. Apatorsen is a product candidate designed to inhibit production of heat shock protein 27 (Hsp27). OGX-225 is a product candidate designed to inhibit the production of Insulin Growth Factor Binding Proteins-2 and -5 (IGFBP-2, IGFBP-5).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: OGXI
  • CUSIP: 68230A10
Key Metrics:
  • Previous Close: $0.47
  • 50 Day Moving Average: $0.546
  • 200 Day Moving Average: $0.502
  • 52-Week Range: $0.33 - $1.42
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -0.82
  • P/E Growth: 0.000
  • Market Cap: $14.05M
  • Outstanding Shares: 30,086,000
  • Beta: 1.79
Profitability:
  • Net Margins: -94.64%
  • Return on Equity: -50.34%
  • Return on Assets: -33.95%
Debt:
  • Current Ratio: 3.24%
  • Quick Ratio: 3.24%

Analyst Ratings

Consensus Ratings for OncoGenex Pharmaceuticals (NASDAQ:OGXI) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for OncoGenex Pharmaceuticals (NASDAQ:OGXI)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
1/22/2016Needham & Company LLCLower Price TargetBuy$6.00 -> $3.00N/AView Rating Details
1/21/2016Royal Bank of CanadaLower Price TargetSector Perform$1.60 -> $1.00N/AView Rating Details
12/2/2015Stifel NicolausDowngradeBuy -> HoldN/AView Rating Details
9/24/2015William BlairReiterated RatingBuy$6.00N/AView Rating Details
(Data available from 3/29/2015 forward)

Earnings

Earnings History for OncoGenex Pharmaceuticals (NASDAQ:OGXI)
Earnings by Quarter for OncoGenex Pharmaceuticals (NASDAQ:OGXI)
Earnings History by Quarter for OncoGenex Pharmaceuticals (NASDAQ:OGXI)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/10/2017        
11/10/2016Q316($0.26)($0.12)ViewN/AView Earnings Details
8/4/2016Q216($0.22)($0.23)$1.17 million$2.10 millionViewN/AView Earnings Details
5/12/2016Q116($0.12)($0.12)$4.09 million$2.90 millionViewListenView Earnings Details
3/9/2016Q4($0.15)($0.06)ViewN/AView Earnings Details
11/12/2015Q3($0.17)($0.16)ViewListenView Earnings Details
8/13/2015Q2$0.34($0.26)ViewListenView Earnings Details
5/14/2015Q115($0.34)($0.20)$4.66 million$1.40 millionViewListenView Earnings Details
3/26/2015Q414($0.30)($0.27)$4.30 million$5.70 millionViewN/AView Earnings Details
10/30/2014($0.38)($0.23)ViewN/AView Earnings Details
8/7/2014($0.55)($0.47)ViewN/AView Earnings Details
4/30/2014($0.50)($0.59)ViewN/AView Earnings Details
3/11/2014Q113($0.66)($0.45)$10.20 million$8.60 millionViewN/AView Earnings Details
11/8/2012Q312($0.49)($0.40)$4.52 million$6.57 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for OncoGenex Pharmaceuticals (NASDAQ:OGXI)
Current Year EPS Consensus Estimate: $-0.780 EPS
Next Year EPS Consensus Estimate: $-0.570 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.07)($0.07)($0.07)
Q2 20161($0.27)($0.27)($0.27)
Q3 20161($0.28)($0.28)($0.28)
Q4 20161($0.28)($0.28)($0.28)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for OncoGenex Pharmaceuticals (NASDAQ:OGXI)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for OncoGenex Pharmaceuticals (NASDAQ:OGXI)
Insider Ownership Percentage: 3.30%
Institutional Ownership Percentage: 18.54%
Insider Trades by Quarter for OncoGenex Pharmaceuticals (NASDAQ:OGXI)
Institutional Ownership by Quarter for OncoGenex Pharmaceuticals (NASDAQ:OGXI)
Insider Trades by Quarter for OncoGenex Pharmaceuticals (NASDAQ:OGXI)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/19/2016John BencichCFOSell1,380$0.57$786.60View SEC Filing  
6/13/2016Cindy JacobsCMOSell1,437$1.03$1,480.11View SEC Filing  
6/13/2016Scott Daniel CormackCEOSell4,856$1.03$5,001.68View SEC Filing  
3/15/2016Cindy JacobsCMOSell3,254$0.83$2,700.82View SEC Filing  
3/15/2016John BencichCFOSell834$0.83$692.22View SEC Filing  
3/15/2016Scott Daniel CormackCEOSell12,033$0.83$9,987.39View SEC Filing  
8/18/2015John BencichCFOSell1,427$2.76$3,938.52View SEC Filing  
6/12/2015Cindy JacobsCMOSell1,408$2.69$3,787.52View SEC Filing  
6/12/2015Scott Daniel CormackCEOSell4,571$2.69$12,295.99View SEC Filing  
5/20/2015Cindy JacobsCMOSell2,092$1.88$3,932.96View SEC Filing  
5/20/2015Scott Daniel CormackCEOSell7,543$1.88$14,180.84View SEC Filing  
8/13/2014Cindy JacobsCMOSell5,650$3.17$17,910.50View SEC Filing  
8/13/2014Scott Daniel CormackCEOSell18,341$3.17$58,140.97View SEC Filing  
3/17/2014Cindy JacobsCMOSell1,250$12.25$15,312.50View SEC Filing  
3/17/2014Scott Daniel CormackCEOSell4,634$12.25$56,766.50View SEC Filing  
8/19/2013Cindy JacobsCMOSell1,364$8.68$11,839.52View SEC Filing  
8/19/2013Scott Daniel CormackCEOSell3,112$8.68$27,012.16View SEC Filing  
3/12/2013Scott Daniel CormackCEOSell2,134$11.90$25,394.60View SEC Filing  
8/15/2012Jack GoldsteinDirectorBuy1,000$14.38$14,380.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for OncoGenex Pharmaceuticals (NASDAQ:OGXI)
Latest Headlines for OncoGenex Pharmaceuticals (NASDAQ:OGXI)
Source:
DateHeadline
prnewswire.com logoBiotech Stocks Under Scanner -- BioDelivery Sciences, Sage Therapeutics, Benitec Biopharma, and OncoGenex Pharma
www.prnewswire.com - March 24 at 8:38 AM
finance.yahoo.com logoAchieve Life Sciences and OncoGenex Pharmaceuticals Announce Cytisine Symposium at the Annual Society …
finance.yahoo.com - March 8 at 9:20 AM
finance.yahoo.com logoAchieve Life Sciences and OncoGenex Pharmaceuticals Announce Cytisine Symposium at the Annual Society for Research in Nicotine and Tobacco Conference ("SRNT")
finance.yahoo.com - March 8 at 9:20 AM
finance.yahoo.com logoONCOGENEX PHARMACEUTICALS, INC. Financials
finance.yahoo.com - March 1 at 7:13 PM
finance.yahoo.com logoAchieve Life Science and OncoGenex Pharmaceuticals Announce Strategic Collaboration with the National …
finance.yahoo.com - March 1 at 10:23 AM
biz.yahoo.com logoONCOGENEX PHARMACEUTICALS, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rul
us.rd.yahoo.com - March 1 at 10:23 AM
us.rd.yahoo.com logoAchieve Life Science and OncoGenex Pharmaceuticals Announce Strategic Collaboration with the National Institutes of Health to Advance the Development of Cytisine for Smoking Cessation
us.rd.yahoo.com - March 1 at 10:23 AM
biz.yahoo.com logoQ4 2016 OncoGenex Pharmaceuticals Inc Earnings Release - After Market Close
us.rd.yahoo.com - February 23 at 9:21 AM
finance.yahoo.com logoOncoGenex Pharmaceuticals, Inc. Reports Financial Results for Year End 2016
finance.yahoo.com - February 23 at 9:21 AM
biz.yahoo.com logoONCOGENEX PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statemen
biz.yahoo.com - February 23 at 9:21 AM
us.rd.yahoo.com logoOncoGenex Pharmaceuticals, Inc. Announces Phase 2 Apatorsen Data for Two Clinical Trials Presented at the American Society of Clinical Oncology (ASCO) 2017 Genitourinary Cancers Symposium
us.rd.yahoo.com - February 22 at 7:05 PM
us.rd.yahoo.com logo9:01 am OncoGenex Pharma announces that apatorsen results from two randomized Phase 2 clinical trials were presented at the American Society of Clinical Oncology 2017 Genitourinary Cancers Symposium; Clinical data from trials in bladder and
us.rd.yahoo.com - February 22 at 7:05 PM
finance.yahoo.com logoOncoGenex Pharmaceuticals, Inc. Announces Phase 2 Apatorsen Data for Two Clinical Trials Presented at the ... - Yahoo Finance
finance.yahoo.com - February 21 at 5:51 PM
finance.yahoo.com logoOncoGenex to Report Year End 2016 Financial Results on Feb. 23, 2017
finance.yahoo.com - February 16 at 6:34 PM
bizjournals.com logoAfter reverse takeover, Bothell's OncoGenex changes name, focuses on smoking cessation drug
www.bizjournals.com - January 17 at 7:23 PM
streetinsider.com logoOncoGenex Pharma (OGXI) to Merge with Achieve Life Science - StreetInsider.com
www.streetinsider.com - January 6 at 7:44 PM
biz.yahoo.com logoONCOGENEX PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
biz.yahoo.com - January 6 at 7:44 PM

Social

Frequently Asked Questions for OncoGenex Pharmaceuticals (NASDAQ:OGXI)

What is OncoGenex Pharmaceuticals' stock symbol?

OncoGenex Pharmaceuticals trades on the NASDAQ under the ticker symbol "OGXI."

How were OncoGenex Pharmaceuticals' earnings last quarter?

OncoGenex Pharmaceuticals Inc (NASDAQ:OGXI) issued its quarterly earnings results on Thursday, August, 4th. The company reported ($0.23) earnings per share for the quarter, missing analysts' consensus estimates of ($0.22) by $0.01. The business had revenue of $2.10 million for the quarter, compared to analysts' expectations of $1.17 million. OncoGenex Pharmaceuticals had a negative net margin of 94.64% and a negative return on equity of 50.34%.

When will OncoGenex Pharmaceuticals make its next earnings announcement?

OncoGenex Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, May, 10th 2017.

Who owns OncoGenex Pharmaceuticals stock?

OncoGenex Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (3.45%). Company insiders that own OncoGenex Pharmaceuticals stock include Cindy Jacobs, John Bencich and Scott Daniel Cormack.

Who bought OncoGenex Pharmaceuticals stock? Who is buying OncoGenex Pharmaceuticals stock?

OncoGenex Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC.

How do I buy OncoGenex Pharmaceuticals stock?

Shares of OncoGenex Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of OncoGenex Pharmaceuticals stock cost?

One share of OncoGenex Pharmaceuticals stock can currently be purchased for approximately $0.47.

OncoGenex Pharmaceuticals (OGXI) Chart for Wednesday, March, 29, 2017

This page was last updated on 3/29/2017 by MarketBeat.com Staff